Note: This study is currently only recruiting patients in the hospital.

If you are interested in being notified if this study begins recruiting from the general population, please use the 'I Am Interested' button below.

Psoriatic Arthritis Study

Seeking eligible patients to participate in a study testing a new investigational drug for people with active psoriatic arthritis.

Brigham and Women's Hospital Immune System and Disorders Skin Conditions
7 visits over 37 weeks
Estimated Time Commitment
Any Gender, 18-years or older
May Be Eligible
Gift card up to $525
May Be Offered
Injection or IV, X-ray, Blood draw, Office visit, Personal health tracking
May Be Required
 
I Am Interested I Am Interested I Am Interested

This project is not recruiting.

Overview

What we are studying

The purpose of the study is to test the effect of the study drug (Bimekizumab injection) on psoriatic arthritis.


Why it is important

The study drug, Bimekizumab, is a new drug that may eventually be used in the treatment of psoriatic arthritis. It is investigational, which means that is it still being tested, and has not yet been approved for treatment by the United States Food and Drug Administration (FDA). To date, 968 adults have been given Bimekizumab in studies that included healthy volunteers, as well as study participants with psoriasis, psoriatic arthritis and ankylosing spondylitis.  


What we hope to accomplish

Principal Investigator

Joseph F Merola, MD, MMSc

Brigham and Women's Hospital

Public Profile

Who can participate

Individuals who are 18 years or older and are suffering from psoriatic arthritis, and treatment with certain drugs called anti-TNFs was not effective. Individuals willing to stop taking any current medications for psoriatic arthritis. Individuals in good general health.

Who cannot participate

Women who are pregnant or planning to become pregnant in the next year. Individuals who use recreational drugs. Individuals with major illnesses or conditions. Individuals with a history of bacterial, viral, or fungal infections. Individuals with history of suicidal ideation, behavior, or attempts.

What you may be asked to do

You will receive one injection of the assigned study drug (bimekizumab or placebo) at Baseline Visit (Day 1) followed by one injection every four weeks at all the other visits. However, you will not receive any injection at Week 16. Each injection will be given under the skin (subcutaneous) either on your lower stomach area (abdomen/tummy), the outer side of your upper thighs, or your upper arm. Injection site will be rotated between visits. Some psoriatic arthritis treatments will be prohibited during the study. Your study doctor can tell you more about which medications are allowed.


Project activities may include:

  • Injection or IV
  • X-ray
  • Blood draw
  • Office visit
  • Personal health tracking

Estimated Time Commitment

7 visits over 37 weeks

What You May Get

Participants will receive $75.00 for every visit completed on a gift card.

Location

Brigham Dermatology Associates
221 Longwood Avenue, Boston, MA

Map it!


Travel

  • Accessible by public transportation
  • Parking available

Travel and Parking Details

This location is accessible by the MBTA (green line - E, Longwood Medical Area) and have parking available.

Additional Information

Project Website

https://becompletestudy.com/


ClinicalTrials.gov Identifier

NCT03896581


Study Phase

Phase 3: This project studies a drug or treatment that has already been studied for safety and effectiveness in both healthy volunteers and participants with specific diseases or conditions. It will gather more information about safety and effectiveness. It may look specifically at different groups of people, different dosages, or different combinations of medications or treatments.


Participating Institutions


Funding Source

  • Industry
Top